Mr. Qiang Ge joined Chengdu New Radiomedicine Technology Co., Ltd. in 2016. He is the Vice President of the company.

 Mr. Ge was at the R&D management positions with DiAo Group and other companies. He was in charge of the research and development of four Class I novel drugs and four generic drugs, among which two Class I novel drugs received IND (investigational new drug) approval for clinical trials by China National Medical Products Administration.